Literature DB >> 23571550

Activity of tedizolid (TR-700) against well-characterized methicillin-resistant Staphylococcus aureus strains of diverse epidemiological origins.

Kenneth S Thomson1, Richard V Goering.   

Abstract

The in vitro activities of tedizolid and 10 antistaphylococcal agents were compared against 111 methicillin-resistant Staphylococcus aureus (MRSA) strains from 14 epidemiologically characterized groups. Tedizolid, tigecycline, and daptomycin were the most potent agents, with tedizolid 4-fold more potent than linezolid. Tedizolid, linezolid, and vancomycin were unaffected by epidemiological types. Tigecycline and daptomycin had reduced potency against ST80-MRSA-IV and ST239-MRSA-III, respectively. Overall, tedizolid was highly potent against all MRSA strain types, including those resistant to other classes of drugs.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23571550      PMCID： PMC3716181          DOI： 10.1128/AAC.00274-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci.

Authors:  Iciar Rodríguez-Avial; Esther Culebras; Carmen Betriu; Gracia Morales; Irene Pena; Juan J Picazo
Journal:  J Antimicrob Chemother       Date:  2011-09-27       Impact factor: 5.790

2.  Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges.

Authors:  Steven D Brown; Maria M Traczewski
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

3.  Evaluation of protein A gene polymorphic region DNA sequencing for typing of Staphylococcus aureus strains.

Authors:  B Shopsin; M Gomez; S O Montgomery; D H Smith; M Waddington; D E Dodge; D A Bost; M Riehman; S Naidich; B N Kreiswirth
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

4.  Efficacy of linezolid against methicillin-resistant or vancomycin-insensitive Staphylococcus aureus in a model of hematogenous pulmonary infection.

Authors:  Katsunori Yanagihara; Yukihiro Kaneko; Toyomitsu Sawai; Yoshitsugu Miyazaki; Kazuhiro Tsukamoto; Yoichi Hirakata; Kazunori Tomono; Jun-Ichi Kadota; Takayoshi Tashiro; Ikuo Murata; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

Review 5.  Current challenges in treating MRSA: what are the options?

Authors:  Natasha V D V Ratnaraja; Peter M Hawkey
Journal:  Expert Rev Anti Infect Ther       Date:  2008-10       Impact factor: 5.091

6.  Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus.

Authors:  M C Enright; N P Day; C E Davies; S J Peacock; B G Spratt
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

Review 7.  MRSA prevalence in European healthcare settings: a review.

Authors:  Madeleine Dulon; Frank Haamann; Claudia Peters; Anja Schablon; Albert Nienhaus
Journal:  BMC Infect Dis       Date:  2011-05-20       Impact factor: 3.090
  7 in total
  22 in total

1.  Tedizolid phosphate.

Authors:  Dennis J Cada; Kyle Ingram; Danial E Baker
Journal:  Hosp Pharm       Date:  2014-11

2.  In Vitro Activity of Tedizolid Compared to Linezolid and Five Other Antimicrobial Agents against 332 Anaerobic Isolates, Including Bacteroides fragilis Group, Prevotella, Porphyromonas, and Veillonella Species.

Authors:  Ellie J C Goldstein; C Vreni Merriam; Diane M Citron
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

3.  Activity of Tedizolid in Methicillin-Resistant Staphylococcus epidermidis Experimental Foreign Body-Associated Osteomyelitis.

Authors:  Kyung-Hwa Park; Kerryl E Greenwood-Quaintance; Audrey N Schuetz; Jayawant N Mandrekar; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

4.  Physiologically Based Pharmacokinetic Modeling for Trimethoprim and Sulfamethoxazole in Children.

Authors:  Elizabeth J Thompson; Huali Wu; Anil Maharaj; Andrea N Edginton; Stephen J Balevic; Marjan Cobbaert; Anthony P Cunningham; Christoph P Hornik; Michael Cohen-Wolkowiez
Journal:  Clin Pharmacokinet       Date:  2019-07       Impact factor: 6.447

5.  Radiolabeled Tedizolid Phosphate Liposomes for Topical Application: Design, Characterization, and Evaluation of Cellular Binding Capacity.

Authors:  Merve Karpuz; Evren Atlihan-Gundogdu; E Selin Demir; Zeynep Senyigit
Journal:  AAPS PharmSciTech       Date:  2021-02-02       Impact factor: 3.246

6.  Effects of Tedizolid Phosphate on Survival Outcomes and Suppression of Production of Staphylococcal Toxins in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Necrotizing Pneumonia.

Authors:  Vien T M Le; Hoan N Le; Marcos Gabriel Pinheiro; Kenneth J Hahn; Mary L Dinh; Kajal B Larson; Shawn D Flanagan; Cedric Badiou; Gerard Lina; Christine Tkaczyk; Bret R Sellman; Binh An Diep
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

7.  Combination of Tedizolid and Daptomycin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Model of Simulated Endocardial Vegetations.

Authors:  Jordan R Smith; Juwon Yim; Seth Rice; Kyle Stamper; Razie Kebriaei; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

8.  Activity of Tedizolid in Methicillin-Resistant Staphylococcus aureus Experimental Foreign Body-Associated Osteomyelitis.

Authors:  Kyung-Hwa Park; Kerryl E Greenwood-Quaintance; Jayawant Mandrekar; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

9.  In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China.

Authors:  D J Biedenbach; S K Bouchillon; B Johnson; J Alder; D F Sahm
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-27       Impact factor: 3.267

10.  Comparative Efficacies of Tedizolid Phosphate, Linezolid, and Vancomycin in a Murine Model of Subcutaneous Catheter-Related Biofilm Infection Due to Methicillin-Susceptible and -Resistant Staphylococcus aureus.

Authors:  Arnold S Bayer; Wessam Abdelhady; Liang Li; Rachelle Gonzales; Yan Q Xiong
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.